Keith S. Reisinger mainly focuses on Immunology, Vaccination, Pediatrics, Reactogenicity and Virology. When carried out as part of a general Immunology research project, his work on Immunogenicity, Immunization and Toxoid is frequently linked to work in Sexually transmitted disease and Genital warts, therefore connecting diverse disciplines of study. His study on Vaccine efficacy is often connected to Placebo as part of broader study in Vaccination.
His Pediatrics study combines topics in areas such as Clinical trial, Varicella vaccine, Viral disease and Tolerability, Adverse effect. In his research, Intensive care medicine and Oral administration is intimately related to Randomized controlled trial, which falls under the overarching field of Clinical trial. Keith S. Reisinger focuses mostly in the field of Reactogenicity, narrowing it down to topics relating to Seroconversion and, in certain cases, Hepatitis B vaccine, Hepatitis A vaccine, Hepatitis vaccine and Twinrix.
His scientific interests lie mostly in Immunology, Vaccination, Immunogenicity, Virology and Pediatrics. His Adverse effect research extends to the thematically linked field of Immunology. The Vaccination study combines topics in areas such as Varicella vaccine, Internal medicine and Seroconversion.
Keith S. Reisinger interconnects Titer and Tetanus in the investigation of issues within Immunogenicity. As a part of the same scientific family, Keith S. Reisinger mostly works in the field of Virology, focusing on Haemophilus influenzae and, on occasion, Hepatitis B. His Pediatrics research integrates issues from Clinical trial, Viral disease, Regimen, Tolerability and Randomized controlled trial.
Keith S. Reisinger spends much of his time researching Vaccination, Immunology, Immunogenicity, Adverse effect and Pediatrics. His Vaccination research includes themes of Internal medicine, Tolerability and Meningococcal disease. The study of Immunology is intertwined with the study of Randomized controlled trial in a number of ways.
His Immunogenicity study integrates concerns from other disciplines, such as Titer, Antibody titer, Influenza vaccine, Adjuvant and Seroconversion. His study in Influenza vaccine is interdisciplinary in nature, drawing from both Influenza A virus and Hemagglutination assay. The various areas that Keith S. Reisinger examines in his Pediatrics study include Clinical trial, Milk protein, Regimen, Lactose and Disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Oral oseltamivir treatment of influenza in children.
Richard J. Whitley;Frederick G. Hayden;Keith S. Reisinger;Nancy Young.
Pediatric Infectious Disease Journal (2001)
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
Stan L. Block;Terry Nolan;Carlos Sattler;Eliav Barr.
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.
Margaret B. Rennels;Kathryn M. Edwards;Harry L. Keyserling;Keith S. Reisinger.
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
Robert B. Belshe;William C. Gruber;Paul M. Mendelman;Iksung Cho.
The Journal of Pediatrics (2000)
Correlates of Immune Protection Induced by Live, Attenuated, Cold-Adapted, Trivalent, Intranasal Influenza Virus Vaccine
Robert B. Belshe;William C. Gruber;Paul M. Mendelman;Harshvardhan B. Mehta.
The Journal of Infectious Diseases (2000)
Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
Barbara Kuter;Holly Matthews;Henry Shinefield;Steve Black.
Pediatric Infectious Disease Journal (2004)
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
Keith S. Reisinger;Stan L. Block;Eduardo Lazcano-Ponce;Rudiwilai Samakoses.
Pediatric Infectious Disease Journal (2007)
Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial
David I Bernstein;David A Sack;Edward Rothstein;Keith Reisinger.
The Lancet (1999)
Avidity and Bactericidal Activity of Antibody Elicited by Different Haemophilus influenzae Type b Conjugate Vaccines
Yechiel Schlesinger;Dan M. Granoff;T. V. Murphy;M. T. Osterholm.
Anticipatory Guidance in Pediatric Practice
Keith S. Reisinger;Jill A. Bires.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: